Hyperfine (NASDAQ:HYPR – Get Free Report) and Beta Bionics (NASDAQ:BBNX – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, risk, dividends and valuation.
Insider & Institutional Ownership
15.0% of Hyperfine shares are held by institutional investors. 26.3% of Hyperfine shares are held by insiders. Comparatively, 5.3% of Beta Bionics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
Hyperfine has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Beta Bionics has a beta of 3.37, meaning that its share price is 237% more volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Hyperfine | 1 | 1 | 3 | 0 | 2.40 |
| Beta Bionics | 1 | 4 | 7 | 1 | 2.62 |
Hyperfine currently has a consensus price target of $2.03, indicating a potential upside of 157.38%. Beta Bionics has a consensus price target of $22.45, indicating a potential upside of 1.19%. Given Hyperfine’s higher possible upside, equities analysts plainly believe Hyperfine is more favorable than Beta Bionics.
Profitability
This table compares Hyperfine and Beta Bionics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Hyperfine | -210.75% | -97.88% | -61.81% |
| Beta Bionics | -61.31% | -26.30% | -23.25% |
Valuation & Earnings
This table compares Hyperfine and Beta Bionics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Hyperfine | $11.40 million | 7.35 | -$35.57 million | ($0.38) | -2.08 |
| Beta Bionics | $119.01 million | 8.39 | -$73.20 million | ($1.65) | -13.45 |
Hyperfine has higher earnings, but lower revenue than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.
Summary
Beta Bionics beats Hyperfine on 9 of the 15 factors compared between the two stocks.
About Hyperfine
Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
Receive News & Ratings for Hyperfine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperfine and related companies with MarketBeat.com's FREE daily email newsletter.
